PHARMA: Partnerships and Promising Pipeline Boost Co.
When Stanley Crooke formed Ionis Pharmaceuticals in 1989, he saw the venture as a longshot. He told investors as much.
San Diego-based Escient Pharmaceuticals launched with a $40 million Series A round, which will go toward a pipeline of novel drugs.
San Diego-based Neurana Pharmaceuticals raised $60 million in Series A financing for a relaxant that treats acute, painful muscle spasms.
Solana Beach-based Luna DNA raised $2 million in a new round of funding, led by Illumina Ventures and Arch Venture Partners, it was announced May 8.
The new hires have assumed key positions in two of Maravai LifeSciences operating businesses: TriLink BioTechnologies and Cygnus Technologies.
CalciMedica focuses on calcium release-activated calcium (CRAC) channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.
Seqster's platform standardizes data from electronic medical records (EMRs), wearables, such as FitBit, and genomics reports, such as those produced by companies such as 23andMe.
The Scripps Translational Science Institute (STSI) was awarded $34 million in renewed funding to advance genomic and digital technologies in clinical care.
AMN Healthcare reported $522 million in quarter one revenue, up 6 percent year over year, fueled by higher-than-expected staffing needs.
TRADE: S.D. Cos. Able to Avoid Some of the Complexities
San Diego biotechs are inking deals with Chinese firms to tap into China’s ever-growing demand for groundbreaking drugs.
San Diego-based Dexcom reported a 30 percent year-over-year revenue increase in quarter one results due a sharp increase in international sales.
NuVasive reported $260.5 million in quarter one results, a 4.6 percent year-over year increase, with its core U.S. hardware business showing solid growth.
Nishan de Silva has nearly 20 years of experience in biotechnology, venture capital and healthcare management consulting.
San Diego-based Synthorx — formed around synthetic biology for novel protein therapies — raised $63 million in a Series C round.
New study will look at CBD as a treatment for severe autism.